ONDANSETRON HYDROCHLORIDE by Novartis is 5-ht 3 receptor antagonist. Approved for postoperative nausea and/or vomiting. First approved in 2007.
Drug data last refreshed 21h ago
5-HT 3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT 3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area…
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition
Worked on ONDANSETRON HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.